PHARMACY

Novo Nordisk launches new insulin device

BY Ryan Chavis

NEW YORK — Novo Nordisk has launched a new insulin pen designed for children with diabetes.

The new NovoPen Echo is the first and only prefilled pen device in the United States that allows for half-unit dosing in combination with a memory function, the company said.

This function not only allows for finer dosing adjustment based on the needs of the child, but will also allow parents to see how much insulin their child has taken and how much time has elapsed since the last dose was administered.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Actavis’ Lo Loestrin Fe patent upheld

BY Michael Johnsen

DUBLIN — Actavis last week confirmed that the U.S. District Court for the District of New Jersey found United States Patent No. 7,704,984 (the ‘984 Patent) to be valid and infringed by Lupin Pharmaceuticals and Amneal Pharmaceuticals Abbreviated New Drug Applications (ANDAs) for generic versions of Actavis’ Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets).  

Lo Loestrin Fe is a prescription birth control pill used for the prevention of pregnancy.

"We are pleased that the Court has ruled in our favor and upheld the validity of our patent on Lo Loestrin Fe," said Paul Bisaro, chairman and CEO of Actavis. "The enforcement of our intellectual property rights is a critical tool in our ability to continue to invest in future treatments, and we intend to vigorously defend these rights against any future challenges or appeals."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Greenstone launches authorized generic of Pfizer’s Rapamune

BY Michael Johnsen

PEAPACK, N.J. — Greenstone, a U.S.-based generic pharmaceutical subsidiary of Pfizer, on Tuesday announced the introduction of Sirolimus to its generic pharmaceutical product line. The product is offered in dosage strengths of 0.5mg x 100. 

Greenstone’s Sirolimus product is the authorized generic of, and equivalent to, Pfizer’s Rapamune (sirolimus). 

Sirolimus is indicated for the prophylaxis of organ rejection in patients ages 13 years or older receiving renal transplants. Therapeutic drug monitoring is recommended for all patients receiving sirolimus.

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?